TGF-β signal transduction in oro-facial health and non-malignant disease (part I)

Critical Reviews in Oral Biology and Medicine

Volumn 15, Issue 6, 2004, Pages 324-336

  Prime, S S ^a   Pring, M ^a   Davies, M ^a   Paterson, I C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Disease; Health; Oro facial; TGF

Indexed keywords

FLUOROURACIL; SMAD PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; DNA BINDING PROTEIN; TRANSACTIVATOR PROTEIN;

ANGIOGENESIS; APOPTOSIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; CRANIOFACIAL DEVELOPMENT; DRUG INHIBITION; EXTRACELLULAR MATRIX; FIBROSIS; HUMAN; LICHEN PLANUS; NONHUMAN; ORAL MUCOSAL DISEASE; PATHOGENESIS; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SCAR FORMATION; SCLERODERMA; SIGNAL TRANSDUCTION; WOUND HEALING; ANIMAL; HARD PALATE; METABOLISM; MOUTH DISEASE; PHYSIOLOGY; PRENATAL DEVELOPMENT; TOOTH DEVELOPMENT;

ANIMALS; DNA-BINDING PROTEINS; HUMANS; MOUTH DISEASES; ODONTOGENESIS; PALATE, HARD; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 28744437302     PISSN: 10454411     EISSN: None     Source Type: Journal    
DOI: 10.1177/154411130401500602     Document Type: Review

References (178)

1. Aghdasi B, Ye K, Resnick A, Huang A, Ha HC, Guo X, et al. (2001). FKBP12, the 12 kDA FK506-binding protein, is a physiologic regulator of the cell cycle. Proc Natl Acad Sci USA 98:2425-2430.
2. Annes JP, Munger JS, Rifkin DB (2003). Making sense of TGF-β activation. J Cell Sci 116:217-224.
3. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, et al. (1999). Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory immune response. Nat Cell Biol 1:E117-E119.
4. Atfi A, Djelloul S, Chastre E, Davis R, Gespach C (1997). Evidence for a role of Rho-like GTPases and stress activated protein kinase/c-Jun N-terminal linase (SAPK/JNK) in transforming growth factor β mediated signaling. J Biol Chem 272:1429-1432.
5. Attisano L, Wrana JL (2000). Smads as transcriptional co-modulators. Cur Opin Cell Biol 12:235-243.
6. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL (2000). Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 275:36803-36810.
7. Bandyopadhyay A, Lopez-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, et al. (2002). Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 62:4690-4695.
8. Barton DE, Foellmer BE, Du J, Tamm J, Derynck R, Francke U (1988). Chromosomal mapping of genes for transforming growth factors-β2 and -β3 in man and mouse: dispersion of the TGF-β gene family. Oncogene Res 3:323-331.
9. Beaty TH, Wang H, Hetmansli JB, Fan YT, Zeiger JS, Liang KY, et al. (2001). A case-control study of nonsyndromic oral clefts in Maryland. Ann Epidemiol 11:434-442.
10. Beck LS, DeGuzman L, Lee WP, Xu Y, Siegel MW, Amento EP (1993). One systemic administration of transforming growth factor-β1 reverses age- or glucocorticoid-impaired wound healing. J Clin Invest 92:2841-2849.
11. Blavier L, Lazaryev A, Groffen J, Heisterkamp N, DeClerck YA, Kaartinen V (2001). TGF-β3-induced palatogenesis requires matrix metalloproteinases. Mol Biol 12:1457-1466.
12. Blobe GC, Schiemann WP, Lodish HF (2000). Role of transforming growth factor β in human disease. N Engl J Med 342:1350-1358.
13. Blobe GC, Schiemann WP, Pepin MC, Beauchemin M, Moustakas A, Lodish HF, et al. (2001a). Functional roles for the cytoplasmic domain of the type III TGF-β receptor in regulating TGF-β signalling. J Biol Chem 276:24627-24637.
14. Blobe GC, Liu X, Fang SJ, How T, Lodish HF (2001b). Anovel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. J Biol Chem 276:39608-39617.
15. Bridoux F, Badou A, Saoudi A, Bernard I, Druet E, Pasquier R, et al. (1997). Transforming growth factor beta (TGF-β)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class II specific, regulatory CD4(+) T cell lines. J Exp Med 185:1769-1775.
16. Brunet CL, Sharpe PM, Ferguson MW (1995). Inhibition of TGF-β3 (but not TGF-β1 or TGF-β2) activity prevents normal mouse embryonic palate fusion. Int J Dev Biol 39:345-355.
17. Cambier S, Mu DZ, O'Connell D, Boylen K, Travis W, Liu WH, et al. (2000). Arole for the integrin αvβ8 in the negative regulation of epithelial cell growth. Cancer Res 60:7084-7093.
18. Cassidy N, Fahey M, Prime SS, Smith AJ (1997). Comparative analysis of transforming growth factor-beta (TGF-β) isoforms 1-3 in human and rabbit dentine matrices. Arch Oral Biol 42:219-223.
19. Chai Y, Zhao J, Mogharei A, Xu B, Bringas P Jr, Shuler C, et al. (1999). Inhibition of transforming growth factor-β type II receptor signaling accelerates tooth formation in mouse first branchial arch explants. Mech Dev 86:63-74.
20. Cheifetz S (1999). BMP receptors in limb and tooth formation. Crit Rev Oral Biol Med 10:182-198.
21. Chen CR, Kang Y, Siegel PM, Massagué J (2002). E2F4/5 and p107 as Smad cofactors linking the TGF-β receptor to c-myc repression. Cell 110:19-32.
22. Chen LZ, Hochwald GM, Huang C, Dakin G, Tao H, Cheng C, et al. (1998). Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1. Proc Natl Acad Sci USA 95:12516-12521.
23. Chenevix-Trench G, Jones K, Green AC, Duffey DL, Martin NG (1992). Cleft lip with or without cleft palate: associations with transforming growth factor alpha and retinoic acid receptor. Am J Hum Genet 51:1377-1385.
24. Chiu CJ, Chang ML, Chiang CP, Hahn LJ, Hsieh LL, Chen CJ (2002). Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis. Cancer Epidemiol Biomarkers Prev 11:646-653.
25. Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C, Piccolo S (2003). Links between tumor suppressors: p53 is required for TGF-β gene responses by cooperating with Smads. Cell 113:301-314.
26. Cotton SA, Herrick AL, Jayson MI, Freemont AJ (1998). TGF-β - a role in systemic sclerosis. J Pathol 184:4-6.
27. Cox DA, Kunz S, Cerletti N, McMaster GK, Burk RR (1992). Wound healing in aged animals: effects of locally applied TGF-β2 in different model systems. In: Angiogenesis - key principles. Steiner R, Weisz PB, Langer R, editors. Basel: Birkhauser, pp. 287-295.
28. Cui XM, Chai Y, Chen J, Yamamoto T, Ito Y, Bringas P, et al. (2003). TGF-β3-dependent SMAD2 phosphorylation and inhibition of MEE proliferation during palatal fusion. Dev Dyn 227:387-394.
29. D'Souza RN, Litz M (1995). Analysis of tooth development in mice bearing a TGF-β1 null mutation. Connect Tissue Res 32:41-46.
30. D'Souza RN, Cavender A, Dickinson D, Roberts A, Letterio J (1998). TGF-β1 is essential for the homeostasis of the dentin-pulp complex. Eur J Oral Sci 106:185-191.
31. Dang H, Geiser AG, Letterio JJ, Nakabayashi T, Kong L, Fernandes G, et al. (1995). SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferation in TGF-β knockout mice. J Immunol 155:3205-3212.
32. de Caestecker MP (2004). The transforming growth factor-β superfamily of receptors. Cytokine Growth Factor Rev 15:1-11.
33. de Caestecker MP, Piek E, Roberts AB (2000). Role of transforming growth factor-β signaling in cancer. J Natl Cancer Inst 92:1388-1402.
34. de Souza AP, Trevilatto PC, Scarel-Caminaga RM, de Brito RB, Line SR (2003). Analysis of the TGF-β-1 promoter polymorphism (C-509T) in patients with chronic periodontitis. J Clin Periodont 30:519-523.
35. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM (1998). Direct binding of Smad3 and Smad4 to critical TGF-β inducible elements in the promoter of human plasminogen activator inhibitor type I gene. EMBO J 17:3091-3100.
36. Dennler S, Goumans MJ, ten Dijke P (2002). Transforming growth factor β signal transduction. J Leukocyte Biol 71:731-740.
37. Derynck R, Zhang YE (2003). Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425:577-584.
38. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL (2003). Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 5:410-421.
39. Dong C, Li Z, Alvarez R, Feng XH, Goldschmidt-Clermont PJ (2000). Microtubule binding to Smads may regulate TGF β activity. Mol Cell 5:27-34.
40. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, et al. (2002). Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 99:3908-3913.
41. Dong Y, Tang L, Letterio JJ, Benveniste EN (2001). The Smad3 protein is involved in TGF-β inhibition of class II transactivator and class II MHC expression. J Immunol 167:311-319.
42. Dudas M, Nagy A, Laping NJ, Moustakis A, Kaartinen V (2004). TGF-β3-induced palatal fusion is mediated by Alk-5/Smad pathway. Dev Biol 266:96-108.
43. Dumont N, Bakin AV, Arteaga CL (2003). Autocrine transforming growth factor-β signaling mediates Smad-independent motility in human cancer cells. J Biol Chem 278:3275-3285.
44. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, et al. (2001). Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J Biol Chem 276:12477-12480.
45. Edlund S, Landstrom M, Heldin CH, Aspenstrom P (2002). Transforming growth factor-β-induced mobilization of the actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 13:902-914.
46. Ejeil AL, Gaultier F, Igondjo-Tchen S, Senni K, Pellat B, Godeau G, et al. (2003). Are cytokines linked to collagen breakdown during periodontal disease progression? J Periodontol 74:196-201.
47. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T (1999). Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59:3379-3386.
48. Erickson HP (1993). Gene knockouts of c-src and transforming growth factor β1, and tenascin suggest superfluous, non-functional expression of proteins. J Cell Biol 120:1079-1081.
49. Erlebacher A, Derynck R (1996). Increased expression of TGF-β2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 132:195-210.
50. Feng XH, Zhang Y, Wu RY, Derynck R (1998). The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for Smad3 in TGF-β-induced transcriptional activation. Genes Dev 12:2153-2163.
51. Ferguson MW (1988). Palate development. Development 103:41-60.
52. Fink SP, Mikkola D, Willson JK, Markowitz S (2003). TGF-β-induced nuclear localisation of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene 22:1317-1323.
53. Foncuberta MC, Cagnoni PJ, Brandts CH, Mandanas R, Fields K, Derigs HG, et al. (2001). Topical transforming growth factor-β3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors. J Immunother 24:384-388.
54. Frey RS, Mulder KM (1997). Involvement of ERK2 and SAPK/JNK activation by TGF-β in the negative growth control of breast cancer cells. Cancer Res 57:628-633.
55. Fujii D, Brissenden JE, Derynck R, Francke U (1986). Transforming growth factor-β gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somat Cell Mol Genet 12:281-288.
56. 3-induced chondroitin sulphate proteoglycan mediates palatal shelf adhesion. Dev Biol 250:393-405.
57. Godar S, Horejsi V, Weidle UH, Binder BR, Hansmann C, Stockinger H (1999). M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-β1. Eur J Immunol 29:1004-1013.
58. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, Nishita M, Fujisawa J, Shibuya H, et al. (1999). Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor β induced gene expression. J Biol Chem 274:27161-27167.
59. Hannigan M, Zhan L, Ai Y, Huang CK (1998). The role of p38 MAP kinase in TGF-β1-induced signal transduction in human neutrophils. Biochem Biophys Res Commun 246:55-58.
60. Hartsough MT, Mulder KM (1995). Transforming growth factor β activation of p44 mapk in proliferating cultures of epithelial cells. J Biol Chem 270:7117-7124.
61. Heldin CH, Miyazono K, ten Dijke P (1997). TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature 390:465-471.
62. Higaki M, Shimokado K (1999). Phosphatidylinositol 3-kinase is required for growth factor-induced amino acid uptake by vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19:2127-2132.
63. Holla LI, Fassmann A, Benes P, Halabala T, Znojil V (2002). 5 polymorphisms in the transforming growth factor-β1 gene (TGF-β1) in adult periodontitis. J Clin Periodontol 29:336-341.
64. Hua X, Liu X, Ansari DO, Lodish HF (1998). Synergistic cooperation of TFE3 and smad proteins in TGF-β-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev 12:3084-3095.
65. Huang X, Lee C (2003). From TGF-β to cancer therapy. Curr Drug Targets 4:243-250.
66. Ijichi H, Otsuka M, Tateishi K, Ikenoue T, Kawakami T, Kanai F, et al. (2004). Smad4-independent regulation of p21/WAF1 by transforming growth factor-β. Oncogene 23:1043-1051.
67. Ito Y, Miyazono K (2003). RUNX transcription factors as key targets of TGF-β superfamily signaling. Curr Opin Genet Dev 13:43-47.
68. Itoh S, Thorikay M, Kowanetz M, Moustakas A, Itoh F, Heldin CH, et al. (2003). Elucidation of Smad requirement in transforming growth factor-β type I receptor-induced responses. J Biol Chem 278:3751-3761.
69. Johnson DW, Qumsiyeh M, Benkhalifa M, Marchuk DA (1995). Assignment of human TGF-β type I and type III receptor genes (TGFβR1 and TGFβR3) to 9q33-q34 and 1p32-33, respectively. Genomics 28:356-357.
70. Jonk LJ, Itoh S, Heldin CH, ten Dijke P, Kruijer W (1998). Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-β, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem 273:21145-21152.
71. Kaartinen V, Cui XM, Heisterkamp N, Groffen J, Shuler CF (1997). Transforming growth factor-β3 regulates transdifferentiation of medial edge epithelium during palate fusion and associated degradation of the basement membrane. Dev Dyn 209:255-260.
72. Kahn A, Farah CS, Savage NW, Walsh LJ, Harbrow DJ, Sugerman PB (2003). Th1 cytokines in oral lichen planus. J Oral Pathol Med 32:77-83.
73. Khalil N (1999). TGF-β: from latent to active. Microbes Infect 1:1255-1263.
74. Cip1 by phosphorylation. J Biol Chem 277:29792-29802.
75. King GN (2001). The importance of drug delivery to optimize the effects of bone morphogenetic proteins during periodontal regeneration. Curr Pharm Biotechnol 2:131-142.
76. Koch RM, Roche NS, Parks WT, Ashcroft GS, Letterio JJ, Roberts AB, et al. (2000). Incisional wound healing in transforming growth factor-beta1 null mice. Wound Repair Regen 8:179-191.
77. Koinuma D, Shinozaki M, Komuro A, Goto K, Saitoh M, Hanyu A, et al. (2003). Arkadia amplifies TGF-β superfamily signalling through degradation of Smad7. EMBO J 22:6458-6470.
78. Kreiborg S, Jensen BL, Larson P, Schleidt DT, Darvan T (1999). Anomalies of craniofacial skeleton and teeth in cleidocranial dysplasia. J Craniofac Genet Dev Biol 19:75-79.
79. Kretzschmar M, Doody J, Timokhina I, Massagué J (1999). Amechanism of repression of TGF-β/Smad signaling by oncogenic Ras. Genes Dev 13:804-816.
80. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, et al. (1993). Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90:770-774.
81. Kulkarni AB, Thyagarajan T, Letterio JJ (2002). Function of cytokines within the TGF-β superfamily as determined from transgenic and gene knockout studies in mice. Curr Mol Med 2:303-327.
82. Kurisaki A, Kose S, Yoneda Y, Heldin CH, Moustakas A (2001). Transforming growth factor-β induces nuclear import of Smad3 in an importin-β1 and Ran-dependent manner. Mol Biol Cell 12:1079-1091.
83. Kuruvilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA, Thorbecke GJ (1991). Protective effect of transforming growth factor β1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 88:2918-2921.
84. Lallemand F, Mazars A, Prunier C, Bertrand F, Kornprost M, Gallea S, et al. (2001). Smad7 inhibits the survival nuclear factor kappaB and potentiates apoptosis in epithelial cells. Oncogene 20:879-884.
85. Larisch S, Yi Y, Lotan R, Kerner H, Eimerl S, Parks WT, et al. (2000). A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nat Cell Biol 2:915-921.
86. Lee PS, Chang C, Liu D, Derynck R (2003). Sumoylation of Smad4, the common Smad mediator of transforming growth factor-β family signaling. J Biol Chem 278:27853-27863.
87. Lesot H, Lisi S, Peterkova M, Mitolo V, Ruch JV (2001). Epigenetic signals during odontoblast differentiation. Adv Dent Res 15:8-13.
88. Letterio JJ, Roberts AB (1998). Regulation of immune responses by TGF-β. Annu Rev Immunol 16:137-161.
89. Lidral AC, Romitti PA, Basart AM, Doetschman T, Leysens NJ, Daack-Hirsch S, et al. (1998). Association of MSX1 and TGFβ3 with nonsyndromic clefting in humans. Am J Hum Genet 63:557-568.
90. Lin X, Liang M, Liang YY, Brunicardi FC, Melchior F, Feng XH (2003). Activation of TGF-β signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4. J Biol Chem 278:18714-18719.
91. Lo RS, Massagué J (1999). Ubiquitin-dependent degradation of TGF-β-activated Smad2. Nat Cell Biol 8:472-478.
92. Lutz M, Knaus P (2002). Integration of the TGF-β pathway into the cellular signaling network. Cell Signal 14:977-988.
93. Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S, et al. (1999). The Ski oncoprotein interacts with the Smad proteins to repress TGF-β signaling. Genes Dev 13:2196-2206.
94. Magloire H, Romeas A, Melin M, Couble ML, Bleicher F, Farges JC (2001). Molecular regulation of odontoblast activity under dentin injury. Adv Dent Res 15:46-50.
95. Mason D, Powrie F (1998). Control of immune pathology in regulatory T-cells. Curr Opin Immunol 10:649-655.
96. Massagué J (1990). The transforming growth factor-beta family. Ann Rev Cell Biol 6:597-641.
97. Massagué J (1998). TGF-β signal transduction. Ann Rev Biochem 67:753-791.
98. Massagué J, Blain SW, Roger SL (2000). TGF-β signaling in growth control, cancer, and heritable disorders. Cell 103:295-309.
99. Mathew S, Murty VV, Cheifetz S, George D, Massagué J, Chaganti RS (1994). Transforming growth factor receptor gene TGFβR2 maps to human chromosome band 3p22. Genomics 20:114-115.
100. Mazars A, Lallemand F, Prunier C, Marais J, Ferrand N, Pessah M, et al. (2001). Evidence for a role of the JNK cascade in Smad7-mediated apoptosis. J Biol Chem 276:36797-36803.
101. McCallion RL, Ferguson MWJ (1996). Fetal wound healing and the development of anti-scarring therapies for adult wound healing. In: The molecular and cellular biology of wound repair. Clark RAF, editor. New York: Plenum Press, pp. 561-600.
102. Miyazawa K, Shinozaka M, Hara T, Furuya T, Miyazono K (2002). Two major Smad pathways in TGF-β superfamily signaling. Genes Cells 7:1191-1204.
103. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, et al. (2002). The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1. J Oral Biol 157:493-507.
104. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, et al. (1999). The integrin αvβ6 binds and activates latent TGF-β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96:319-328.
105. Mundlos S (1999). Cleidocranial dysplasia: clinical and molecular genetics. J Med Genet 36:177-182.
106. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, et al (2002). Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109:1551-1559.
107. O'Kane S, Ferguson MW (1997). Transforming growth factor βs and wound healing. Int J Biochem Cell Biol 29:63-78.
108. Pepper MS (1997). Transforming growth factor-beta: vasculogenesis, angiogenesis and vessel wall integrity. Cytokine Growth Factor Rev 8:21-43.
109. Perlman R, Schiemann WP, Brooks MW, Lodish HF, Weinberg RA (2001). TGF-β-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol 3:708-714.
110. Petritsch C, Beug H, Balmain A, Oft M (2000). TGF-β inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest. Genes Dev 14:3093-3101.
111. Pierreux CE, Nicolas FJ, Hill CS (2000). Transforming growth factor β-independent shuttling of Smad4 between cytoplasm and nucleus. Mol Cell Biol 20:9041-9054.
112. Pindborg JJ, Murti PR, Bhonsle RB, Gupta PC, Daftary DK, Mehta FS (1984). Oral submucous fibrosis as a precancerous condition. Scand J Dent Res 92:224-229.
113. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, et al. (1995). Transforming growth factor-β3 is required for secondary palate fusion. Nat Genet 11:409-414.
114. Prud'homme GJ, Piccirillo CA (2000). The inhibitory effects of transforming growth factor-β1 (TGF-β1) in autoimmune diseases. J Autoimmun 14:23-42.
115. Prud'homme GJ, Lawson BR, Theofilopoulos AN (2001). Anticytokine gene therapy of autoimmune diseases. Exp Opin Biol Ther 1:359-373.
116. Quan T, He TY, Kang S, Voorhees JJ, Fisher GJ (2002). Ultraviolet irradiation alters transforming growth factor β/Smad pathway in human skin in vivo. J Invest Dermatol 119:499-506.
117. Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE (1991). Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. J Immunol 146:3012-3017.
118. Reguly T, Wrana JL (2003). In or out? The dynamics of Smad nucleocytoplasmic shuttling. Trends Cell Biol 13:216-220.
119. Reimann T, Hempel U, Krautwald S, Axmann A, Scheibe R, Seidel D, et al. (1997). Transforming growth factor-β1 induces activation of Ras, Raf-1, MEK and MAPK in rat hepatic stellate cells. FEBS Lett 403:57-60.
120. Reynisdottir I, Polyak K, Iavarone A, Massagué J (1995). Kip/Cip and Ink4 inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 9:1831-1845.
121. Robson MC, Phillip LG, Cooper DM, Lyle WG, Robson LE, Odom L, et al. (1995). Safety and effect of transforming growth factor-β2 for treatment of venous stasis ulcers. Wound Rep Reg 3:157-167.
122. Rombouts K, Niki T, Greenwel P, Vandermonde A, Wielant A, Hellemans K, et al. (2002). Trichstatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF- β1-induced fibrogenesis in skin fibroblasts. Exp Cell Res 278:184-197.
123. Romitti PA, Lidral AC, Munger RG, Daack-Hirsch S, Burns TL, Murray JC (1999). Candidate genes for nonsyndromic cleft lip and palate and maternal cigarette smoking and alcohol consumption: evaluation of genotype-environment interactions from a population-based case-control study of orofacial clefts. Teratology 59:39-50.
124. Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, et al. (1995). Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci USA 92:7632-7636.
125. Ruch JV, Lesot H, Bègue-Kirn C (1995). Odontoblast differentiation. Int J Dev Biol 39:51-68.
126. Runyan CE, Schnaper HW, Poncelet AC (2003). Smad3 and PKC{delta} mediate TGF-{beta}1-induced collagen I expression in human mesangial cells. Am J Physiol Renal Physiol 285:F413-422.
127. Saharinen J, Hyytiainen M, Taipale J, Keski-Oja J (1999). Latent transforming growth factor-β binding proteins (LTBPs) - structural extracellular matrix proteins for targeting TGF-β action. Cytokine Growth Factor Rev 10:99-117.
128. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, et al. (1997). TGF-β2 knockout mice have multiple developmental defects that are non-overlapping with other TGF β knockout phenotypes. Development 124:2659-2670.
129. Sano Y, Haraada J, Tashiro S, Gotoh-Mandeville R, Maekawa T, Ishii S (1999). ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor beta signaling. J Biol Chem 274:8949-8957.
130. Sato Y, Rifkin DB (1989). Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecule by plasmin during coculture. J Cell Biol 109:309-315.
131. Savage C, Das P, Finelli AL, Townsend SR, Sun CY, Baird SE, et al. (1996). Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor β pathway components. Proc Natl Acad Sci USA 93:790-794.
132. Sekelsky JJ, Newfield SJ, Raftery LA, Chartoff EH, Gelbart WW (1995). Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 139:1347-1358.
133. Shah M, Foreman DM, Ferguson MW (1992). Control of scarring in adult wounds by neutralising antibody to transforming growth factor β. Lancet 339:213-214.
134. Shah M, Foreman DM, Ferguson MW (1994). Neutralising antibodies to TGF-β1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 107:1137-1157.
135. Shi Y, Massagué J (2003). Mechanisms of TGF-β signalling from cell membrane to the nucleus. Cell 113:685-700.
136. Shi Y, Wang YF, Jayaraman L, Yang H, Massagué J, Pavletich N (1998). Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA-binding in TGF-β signaling. Cell 94:585-594.
137. Shibuya H, Yamaguchi K, Shirakabe K, Tonegawa A, Gotoh Y, Ueno N, et al. (1996). TAB1: an activator of the TAK1 MAPKKK in TGF-β signal transduction. Science 272:1179-1182.
138. Shirakabe K, Yamaguchi K, Shibuya H, Irie K, Matsuda S, Moriguchi T, et al. (1997). TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J Biol Chem 272:8141-8144.
139. Shull MM, Ormsby L, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. (1992). Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359:693-699.
140. Siegel PM, Massagué J (2003). Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nature Rev Cancer 3:807-819.
141. Sieweke MH, Bissell MJ (1994). The tumor-promoting effect of wounding: a possible role for TGF-β-induced stromal alterations. Crit Rev Oncog 5:297-311.
142. Skaleric U, Kramar B, Petelin M, Pavlica Z, Wahl SM (1997). Changes in TGF-β1 levels in gingiva, crevicular fluid and serum associated with periodontal inflammation in humans and dogs. Eur J Oral Sci 105:136-142.
143. Sloan AJ, Matthews JB, Smith AJ (1999). TGF-β receptor expression in human odontoblasts and pulpal cells. Histochem J 31:565-569.
144. Sloan AJ, Perry H, Matthews JB, Smith AJ (2000). Transforming growth factor-β isoform expression in mature human molar teeth. Histochem J 32:247-252.
145. Snowden AW, Perkins ND (1998). Cell cycle regulation of the transcriptional coactivators p300 and CREB binding protein. Biochem Pharmacol 55:1947-1954.
146. Sonis ST, Van Vugt AG, Brien JP, Muska AD, Bruskin AM, Rose A, et al. (1997). Transforming growth factor-β3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol 33:47-54.
147. Souchelnytskyi S, Nakayama T, Nakao A, Moren A, Heldin C, Christian JL, et al. (1998). Physical and functional interaction of murine and Xenopus Smad7 with bone morphogenetic protein receptors and transforming growth factor-β receptors. J Biol Chem 273:25364-25370.
148. Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, et al. (1997). Reciprocal IFN-gamma and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol Today 18:61-64.
149. Sugerman PB, Satterwhite K, Bigby M (2000). Auto-cytotoxic T cell clones in lichen planus. Br J Dermatol 142:449-456.
150. Sugerman PR, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, et al. (2002). The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 13:350-365.
151. Sun D, Vanderburg CR, Odierna GS, Hay ED (1998). TGFβ3 promotes transformation of chicken palate medial edge epithelium to mesenchyme in vitro. Development 125:95-105.
152. Sykaras N, Opperman LA (2003). Bone morphogenetic proteins (BMPs): how do they function and what can they offer the clinician? J Oral Sci 45:57-73.
153. Takatsu Y, Nakamura M, Stapleton M, Danos MC, Matsumoto K, O'Connor MB, et al. (2000). TAK1 participates in c-Jun N-terminal kinase signaling during Drosophila development. Mol Cell Biol 20:3015-3026.
154. Taya Y, O'Kane S, Ferguson MW (1999). Pathogenesis of cleft palate in TGF-β3 knockout mice. Development 126:3869-3879.
155. ten Dijke P, Goumans MJ, Itoh F, Itoh S (2002). Regulation of cell proliferation by Smad proteins. J Cell Physiol 191:1-16.
156. Thyagarajan T, Sreenath T, Cho A, Wright JT, Kulkarni AB (2001). Reduced expression of dentin sialophosphoprotein is associated with dysplastic dentin in mice overexpressing transforming growth factor-β1 in teeth. J Biol Chem 276:11016-11020.
157. Tsang M, Kim R, de Caestecker MP, Kudoh T, Roberts AB, Dawid IB (2000). Zebrafish NMA is involved in TGFbeta family signaling. Genesis 28:47-57.
158. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL (1998). SARA, a FYVE domain protein that recruits Smad2 to the TGF-β receptor. Cell 95:779-791.
159. Ulloa L, Doody J, Massagué J (1999). Inhibition of transforming growth factor-β/SMAD signaling by the interferon-γ/STAT pathway. Nature 397:710-713.
160. Verrecchia F, Mauviel A (2002). Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118:211-215.
161. Vindevoghel L, Lechleider RJ, Kon A, de Caestecker MP, Uitto J, Roberts AB, et al. (1998). SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor β. Proc Natl Acad Sci USA 95:14769-14774.
162. Wang T, Donahoe PK (2004). The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors. Front Biosci 9:619-631.
163. Watanabe M, Masuyama N, Fukuda M, Nishida E (2000). Regulation of intracellular dynamics of Smad4 by its leucine-rich nuclear export signal. EMBO Rep 1:176-182.
164. Workman JL, Kingston RE (1998). Alteration of nucleosome structure as a mechanism of transcriptional regulation. Ann Rev Biochem 67:545-579.
165. Wotton D, Lo RS, Swaby LA, Massagué J (1999). Multiple modes of repression by the Smad transcriptional corepressor TGIF. J Biol Chem 274:37105-37110.
166. Xiao Z, Liu X, Henis YI, Lodish HF (2000). A distinct nuclear localization signal in the N terminus of Smad3 determines its ligand-induced nuclear translocation. Proc Natl Acad Sci USA 97:7853-7858.
167. Xiao Z, Latek R, Lodish H (2003). An extended bipartite nuclear localization signal in Smad4 is required for its nuclear import and transcriptional activity. Oncogene 22:1057-1069.
168. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, et al. (1995). Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270:2008-2011.
169. Yamaguchi K, Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K, et al. (1999). XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J 18:179-187.
170. Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, et al. (1999). Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283:1317-1321.
171. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, et al. (1999). Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J 18:1280-1291.
172. Yang Y, Dukhanina O, Tang B, Mamura M, Letterio J, MacGregor J, et al. (2002). Lifetime exposure to a soluble TGF-β antagonist protects mice against metastases without adverse side effects. J Clin Invest 109:1607-1615.
173. Yang YC, Piek E, Zavadil J, Liang D, Xie D, Heyer J, et al. (2003). Hierarchical model of gene regulation by transforming growth factor β. Proc Natl Acad Sci USA 100:10269-10274.
174. Yoo J, Ghiassi M, Jirmanova L, Balliet AG, Hoffman B, Fornace AJ, et al. (2003). TGF-β-induced apoptosis is mediated by Smad-dependent expression of GADD45B through p38 activation. J Biol Chem 278:43001-43007.
175. Yu L, Hebert MC, Zhang YE (2002) TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J 21:3749-3759.
176. Zhang Y, Feng XH, Derynck R (1998). Smad3 and Smad4 co-operate with c-Jun/c-Fos to mediate TGF-β-induced transcription. Nature 394:909-913.
177. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R (2001). Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 98:974-979.
178. Zhou G, Lee SC, Yao Z, Tan TH (1999). Hematopoietic progenitor kinase 1 is a component of transforming growth factor β-induced c-Jun N-terminal kinase signaling cascade. J Biol Chem 274:13133-13138.